Logo image of ME

23ANDME HOLDING CO -CLASS A (ME) Stock Fundamental Analysis

NASDAQ:ME - Nasdaq - US90138Q3065 - Common Stock - Currency: USD

0.6063  -0.16 (-21.26%)

After market: 0.5 -0.11 (-17.53%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ME. ME was compared to 102 industry peers in the Health Care Providers & Services industry. The financial health of ME is average, but there are quite some concerns on its profitability. ME is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ME has reported negative net income.
In the past year ME has reported a negative cash flow from operations.
ME had negative earnings in each of the past 5 years.
ME had a negative operating cash flow in each of the past 5 years.
ME Yearly Net Income VS EBIT VS OCF VS FCFME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

The Return On Assets of ME (-138.01%) is worse than 93.64% of its industry peers.
Looking at the Return On Equity, with a value of -545.25%, ME is doing worse than 86.36% of the companies in the same industry.
Industry RankSector Rank
ROA -138.01%
ROE -545.25%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ME Yearly ROA, ROE, ROICME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

ME has a Gross Margin of 52.58%. This is in the better half of the industry: ME outperforms 78.18% of its industry peers.
In the last couple of years the Gross Margin of ME has remained more or less at the same level.
ME does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 52.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.93%
GM growth 5Y0.67%
ME Yearly Profit, Operating, Gross MarginsME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

ME does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for ME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ME Yearly Shares OutstandingME Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 100M 200M 300M 400M
ME Yearly Total Debt VS Total AssetsME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

ME has an Altman-Z score of -13.45. This is a bad value and indicates that ME is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -13.45, ME is not doing good in the industry: 90.91% of the companies in the same industry are doing better.
ME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.45
ROIC/WACCN/A
WACC8.71%
ME Yearly LT Debt VS Equity VS FCFME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

ME has a Current Ratio of 1.11. This is a normal value and indicates that ME is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ME (1.11) is worse than 68.18% of its industry peers.
ME has a Quick Ratio of 1.11. This is a bad value and indicates that ME is not financially healthy enough and could expect problems in meeting its short term obligations.
ME has a Quick ratio of 0.96. This is in the lower half of the industry: ME underperforms 69.09% of its industry peers.
Industry RankSector Rank
Current Ratio 1.11
Quick Ratio 0.96
ME Yearly Current Assets VS Current LiabilitesME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

ME shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -29.41%.
The Revenue for ME has decreased by -15.83% in the past year. This is quite bad
Measured over the past years, ME shows a very negative growth in Revenue. The Revenue has been decreasing by -13.01% on average per year.
EPS 1Y (TTM)-29.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-197.53%
Revenue 1Y (TTM)-15.83%
Revenue growth 3Y-3.43%
Revenue growth 5Y-13.01%
Sales Q2Q%34.67%

3.2 Future

The Earnings Per Share is expected to grow by 25.35% on average over the next years. This is a very strong growth
Based on estimates for the next years, ME will show a quite strong growth in Revenue. The Revenue will grow by 19.08% on average per year.
EPS Next Y-329.17%
EPS Next 2Y-99.49%
EPS Next 3Y25.35%
EPS Next 5YN/A
Revenue Next Year22.44%
Revenue Next 2Y19.85%
Revenue Next 3Y5.77%
Revenue Next 5Y19.08%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ME Yearly Revenue VS EstimatesME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
ME Yearly EPS VS EstimatesME Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ME. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ME Price Earnings VS Forward Price EarningsME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ME Per share dataME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40

4.3 Compensation for Growth

A more expensive valuation may be justified as ME's earnings are expected to grow with 25.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-99.49%
EPS Next 3Y25.35%

More info and screens

0

5. Dividend

5.1 Amount

ME does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

23ANDME HOLDING CO -CLASS A

NASDAQ:ME (3/28/2025, 8:00:00 PM)

After market: 0.5 -0.11 (-17.53%)

0.6063

-0.16 (-21.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners24.69%
Inst Owner Change-66.19%
Ins Owners9.89%
Ins Owner Change-0.04%
Market Cap16.27M
Analysts37.78
Price Target2.12 (249.66%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.94%
Min Revenue beat(2)-5.66%
Max Revenue beat(2)1.78%
Revenue beat(4)2
Avg Revenue beat(4)-4.8%
Min Revenue beat(4)-24.62%
Max Revenue beat(4)9.3%
Revenue beat(8)4
Avg Revenue beat(8)-6%
Revenue beat(12)6
Avg Revenue beat(12)-3.09%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-94.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.08
P/FCF N/A
P/OCF N/A
P/B 0.23
P/tB 0.73
EV/EBITDA N/A
EPS(TTM)-13.2
EYN/A
EPS(NY)-52.53
Fwd EYN/A
FCF(TTM)-6.05
FCFYN/A
OCF(TTM)-5.76
OCFYN/A
SpS7.78
BVpS2.62
TBVpS0.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -138.01%
ROE -545.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 52.58%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.93%
GM growth 5Y0.67%
F-Score4
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.25%
Cap/Sales 3.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.11
Quick Ratio 0.96
Altman-Z -13.45
F-Score4
WACC8.71%
ROIC/WACCN/A
Cap/Depr(3y)39.05%
Cap/Depr(5y)93.91%
Cap/Sales(3y)4.44%
Cap/Sales(5y)8.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-197.53%
EPS Next Y-329.17%
EPS Next 2Y-99.49%
EPS Next 3Y25.35%
EPS Next 5YN/A
Revenue 1Y (TTM)-15.83%
Revenue growth 3Y-3.43%
Revenue growth 5Y-13.01%
Sales Q2Q%34.67%
Revenue Next Year22.44%
Revenue Next 2Y19.85%
Revenue Next 3Y5.77%
Revenue Next 5Y19.08%
EBIT growth 1Y37.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.46%
EBIT Next 3Y21.64%
EBIT Next 5YN/A
FCF growth 1Y2.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.64%
OCF growth 3YN/A
OCF growth 5YN/A